


Edited by Bernd Groner

 WILEY-VCH

Peptides as Drugs

Discovery and Development



R914
P424

Peptides as Drugs

Discovery and Development

Edited by
Bernd Groner



WILEY-
VCH



E2010000109

WILEY-VCH Verlag GmbH & Co. KGaA

The Editor

Prof. Dr. Bernd Groner

Georg-Speyer-Haus
Paul-Ehrlich-Straße 42 -44
60596 Frankfurt
Germany

Cover

The cover shows a cartoon illustration of two protein strands (in blue and yellow respectively) whose interaction is competitively inhibited by a peptide (in red).

■ All books published by Wiley-VCH are carefully produced. Nevertheless, authors, editors, and publisher do not warrant the information contained in these books, including this book, to be free of errors. Readers are advised to keep in mind that statements, data, illustrations, procedural details or other items may inadvertently be inaccurate.

Library of Congress Card No.:

applied for

British Library Cataloguing-in-Publication Data

A catalogue record for this book is available from the British Library.

Bibliographic information published by the Deutsche Nationalbibliothek

The Deutsche Nationalbibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data are available on the Internet at <<http://dnb.d-nb.de>>.

© 2009 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim

All rights reserved (including those of translation into other languages). No part of this book may be reproduced in any form – by photoprinting, microfilm, or any other means – nor transmitted or translated into a machine language without written permission from the publishers. Registered names, trademarks, etc. used in this book, even when not specifically marked as such, are not to be considered unprotected by law.

Composition SNP Best-set Typesetter Ltd., Hong Kong

Printing Strauss GmbH, Mörlenbach

Bookbinding Litges & Dopf GmbH, Heppenheim

Cover Design Adam Design, Weinheim

Printed in the Federal Republic of Germany
Printed on acid-free paper

ISBN 978-3-527-32205-3

Peptides as Drugs

Edited by
Bernd Groner

Further Reading

Sewald, N., Jakubke, H.-D.

Peptides: Chemistry and Biology

2009

ISBN: 978-3-527-31867-4

Jakubke, H.-D., Sewald, N.

Peptides from A to Z

A Concise Encyclopedia

2008

ISBN: 978-3-527-31722-6

Mannhold, R. (ed.)

Molecular Drug Properties

Measurement and Prediction

Volume 37 of Series "Methods and Principles in Medicinal Chemistry" edited by Mannhold, R., Kubinyi, H., Folkers, G.

2008

ISBN: 978-3-527-31755-4

Van de Waterbeemd, H. Testa, B. (eds.)

Drug Bioavailability

Estimation of Solubility, Permeability, Absorption and Bioavailability

Volume 40 of Series "Methods and Principles in Medicinal Chemistry" edited by Mannhold, R., Kubinyi, H., Folkers, G.

2009

ISBN: 978-3-527-32051-6

Ottow, E., Weinmann, H. (eds.)

Nuclear Receptors as Drug Targets

Volume 39 of Series "Methods and Principles in Medicinal Chemistry" edited by Mannhold, R., Kubinyi, H., Folkers, G.

2008

ISBN: 978-3-527-31872-8

Rognan, D. (ed.)

Ligand Design for G Protein-coupled Receptors

Volume 30 of Series "Methods and Principles in Medicinal Chemistry" edited by Mannhold, R., Kubinyi, H., Folkers, G.

2006

ISBN: 978-3-527-31284-9

Bertau, M., Mosekilde, E., Westerhoff, H. V.

Biosimulation in Drug Development

2008

ISBN: 978-3-527-31699-1

Fischer, J., Ganellin, C. R. (eds.)

Analogue-based Drug Discovery

2006

ISBN: 978-3-527-31257-3

Preface

The biological revolution of the past three decades has provided spectacular insights into the structure and function of macromolecules, cells and organisms, has changed our appreciation of the material basis of life, and has also provided the tools for targeted interferences with cellular processes. The technological advances which made this progress possible are based on, for example, molecular cloning, DNA sequencing, and the genetic manipulations of cells and organisms, and these methods have always preceded—or at least have accompanied—major conceptual advances.

Today, these successes in individual areas of biology are being extrapolated, and highly ambitious system biology projects have been initiated which will attempt to describe how the function of individual genes and the entirety of their interactions result in quantitative phenotypes of particular cells or organisms. The efforts to gain insights into quantitative behaviors are still restricted to simple model organisms and a few well-defined signal transduction pathways. Genetic manipulations are used to study information transmission through signaling systems, and to interpret them in the light of the resulting phenotypes. Interdisciplinary collaborations aim at identifying and predicting responses, and formulating new hypotheses concerning system functions.

Despite this remarkable progress in almost all areas of biology, reasonable predictions about gene functions in the organismal context remain very difficult. Whilst it is possible to annotate genes, and to recognize particular functional domains or subcellular localization signals, the cell-type specificity of expression, the regulation of expression, and the contribution of individual genes to particular phenotypic manifestations remain to be determined on an empirical basis. This has important implications for the development and use of drugs because, even if a drug can be developed to target a molecule that plays a central role in a particular pathological process, the adverse side effects of such a drug might still be unpredictable.

In life, if problems are very complex and the methods to approach them are still not fully developed, then there is a temptation to say “It can’t be done”. The Human Genome Project and targeted homologous recombination in embryonal stem cells are two such examples. But, in hindsight, advances in technologies tend to make the skeptic appear timid. Whilst the need to develop new drugs, to exploit additional drug targets and to meet medical needs is undisputed, many hurdles persist which

might deter the use of a bold approach. One criterion which is most important for the decision makers is that of *oral bioavailability*. The design of small-molecular-weight compounds takes into consideration the “rule-of-five” (“Lipinski’s rule of drug-likeness”), and this has had a profound influence on the thinking of medicinal chemists. Biologically active small molecules and drugs are many optimization steps apart, and sometimes even incompatible. Their pharmacokinetic properties clearly must be considered at an early stage in the development process, but this can also can stifle innovation. “Drug-likeness” and “druggability” represent two most valuable concepts, and the majority of the successful small-molecular-weight compounds are seen to adhere to certain rules which, if applied dogmatically, may tend to eliminate many possible target structures, even from only a theoretical consideration. It should be borne in mind that these rules are not absolute, and do not extend to biological substances—for example, in recent years monoclonal antibodies have become not only clinically successful but also commercially viable. Future drug discoveries will undoubtedly include more unconventional approaches, particularly in those cases where small-molecular-weight compounds with ideally defined properties have not yet been identified.

The versatility of protein functions and the power of peptides might represent a good starting point for considering some new options. Proteins are often composed of multiple functional domains which can operate independently of each other. Indeed, their autonomous functions are often based on the formation of distinct structures and conformations which are independent from any accompanying domains. Such domains can vary from 25 to 500 amino acids, and be stabilized with the help of metal ions or disulfide bridges. They also often embody functional units and act autonomously and, for this reason, can be taken out of context and recombined with other functional domains to yield new proteins with novel properties. Such characteristics of peptides can be exploited for practical purposes, notably the design of highly specific ligands and inhibitors. Peptide ligands may function as either agonists or antagonists, and in turn can influence protein conformations, protein interactions, or their DNA-binding properties. Upon the identification of a useful target structure, peptides recognizing this structure can be assembled into carriers or scaffolds and delivered as therapeutic proteins.

The design and production of *Peptides as Drugs* appears at first sight much like many of the seemingly insurmountable problems associated with novel approaches. Yet, this volume shows not only that such problems are currently being addressed, but also that many important contributions have in fact already been elucidated. It is inevitable that, in the foreseeable future, peptides will find their way into the drug repertoire, at which point “It can’t be done” will be replaced by “It has been done”. And, perhaps unsurprisingly, when this new class of drugs reaches the clinic and helps to improve existing therapies, then everybody will be convinced it was “... a good idea to begin with”.

List of Contributors

Yvonne Becker

Georg Speyer Haus
Institute for Biomedical Research
Paul Ehrlich Straße 42
60596 Frankfurt am Main
Germany

Corina Borghouts

Georg Speyer Haus
Institute for Biomedical Research
Paul Ehrlich Straße 42
60596 Frankfurt am Main
Germany

Ursula Dietrich

Georg Speyer Haus
Institute for Biomedical Research
Paul Ehrlich Straße 42
60596 Frankfurt am Main
Germany

Susanne Dymalla

German Cancer Research
Center
Molecular Therapy of Virus-
Associated Cancers (F065)
Im Neuenheimer Feld 242
69120 Heidelberg
Germany

Lisa Egerer

Georg Speyer Haus
Institute for Biomedical Research
Paul Ehrlich Straße 42
60596 Frankfurt am Main
Germany

Elo Eriste

University of Tartu
Institute of Technology
Nooruse 1
50411 Tartu
Estonia

Manuel Grez

Georg Speyer Haus
Institute for Biomedical Research
Paul Ehrlich Straße 42
60596 Frankfurt am Main
Germany

Bernd Groner

Georg Speyer Haus
Institute for Biomedical Research
Paul Ehrlich Straße 42
60596 Frankfurt am Main
Germany

Joachim Grötzinger

Christian-Albrechts-University
Kiel
Institute of Biochemistry
Olshausenstraße 40
24098 Kiel
Germany

Mats Hansen

Stockholm University
Department of Neurochemistry
Svante Arrheniusv. 21A
10691 Stockholm
Sweden
University of Tartu
Institute of Technology
Nooruse 1
50411 Tartu
Estonia

Felix Hoppe-Seyler

German Cancer Research Center
Molecular Therapy of Virus-
Associated Cancers (F065)
Im Neuenheimer Feld 242
69120 Heidelberg
Germany

Karin Hoppe-Seyler

German Cancer Research Center
Molecular Therapy of Virus-
Associated Cancers (F065)
Im Neuenheimer Feld 242
69120 Heidelberg
Germany

Anne Hubert

Georg Speyer Haus
Institute for Biomedical Research
Paul Ehrlich Straße 42
60596 Frankfurt am Main
Germany

Joachim Koch

Georg Speyer Haus
Institute for Biomedical Research
Paul Ehrlich Straße 42
60596 Frankfurt am Main
Germany

Dorothee von Laer

Georg Speyer Haus
Institute for Biomedical Research
Paul Ehrlich Straße 42
60596 Frankfurt am Main
Germany

Ülo Langel

Stockholm University
Department of Neurochemistry
Svante Arrheniusv. 21A
10691 Stockholm
Sweden
University of Tartu
Institute of Technology
Nooruse 1
50411 Tartu
Estonia

Markus A. Moosmeier

German Cancer Research Center
Molecular Therapy of Virus-Associated
Cancers (F065)
Im Neuenheimer Feld 242
69120 Heidelberg
Germany

Véronique Orian-Rousseau

Forschungszentrum Karlsruhe
Institute of Technology and Genetics
P.O. Box 3640
76021 Karlsruhe
Germany

Helmut Ponta

Forschungszentrum Karlsruhe
Institute of Technology and
Genetics
P.O. Box 3640
76021 Karlsruhe
Germany

Stefan Rose-John

Christian-Albrechts-University
Kiel
Institute of Biochemistry
Olshausenstraße 40
24098 Kiel
Germany

Jürgen Scheller

Christian-Albrechts-University
Kiel
Institute of Biochemistry
Olshausenstraße 40
24098 Kiel
Germany

Mike Schutkowski

JPT Peptide Technologies GmbH
Volmerstrasse 5
12489 Berlin
Germany

Alexandra Thiele

Max-Planck Research Unit for
Enzymology of Protein Folding
Weinbergweg 22
06120 Halle
Germany

Astrid Weiss

Georg Speyer Haus
Institute for Biomedical Research
Paul Ehrlich Straße 42
60596 Frankfurt am Main
Germany

Christian Wichmann

Georg Speyer Haus
Institute for Biomedical Research
Paul Ehrlich Straße 42
60596 Frankfurt am Main
Germany

Contents

Prefacce *xi*

List of Contributors *xiii*

- 1 Peptides as Drugs: Discovery and Development** 1
Bernd Groner
- 1.1 Discovery of New Potential Drug Targets and the Limitations of Druggability 1
- 1.2 Protein Interaction Domains Are at the Core of Signaling Pathways 4
- 1.3 Peptides as Inhibitors of Protein Interactions 5
References 7
- 2 Mimics of Growth Factors and Cytokines** 9
Jürgen Scheller, Joachim Grötzinger, and Stefan Rose-John
- 2.1 Introduction 9
- 2.2 The Cytokines 9
- 2.2.1 The Receptors 11
- 2.2.2 “Simple” Receptors 12
- 2.2.3 “Complex” Receptors 13
- 2.3 Defining Receptor Recognition Sites in Cytokines Using Chimeric Proteins 15
- 2.4 Receptor Recognition Sites are Organized as Exchangeable Modules 17
- 2.5 The Concept of Fusing the Cytokine to the Soluble Receptor: Hyper-IL-6 19
- 2.6 Antagonists Specifically Inhibiting IL-6 Trans-Signaling 20
- 2.7 *In Vitro* Evolution of Peptides and Proteins 22
- 2.7.1 Platforms for the Selection of High-Affinity Binders 24
- 2.7.2 Agonists and Antagonists of Cytokines and Growth Hormones 27
- 2.8 Concluding Remarks 28
References 29

3	Peptides Derived from Exon v6 of the CD44 Extracellular Domain Prevent Activation of Receptor Tyrosine Kinase and Subsequently Angiogenesis and Metastatic Spread of Tumor Cells	35
	<i>Helmut Ponta and Véronique Orian-Rousseau</i>	
3.1	Introduction	35
3.2	CD44 Proteins and Their Involvement in RTK Activation	36
3.3	CD44v6 Acts as a Coreceptor for c-Met and Ron	37
3.4	Three Amino Acids in CD44 Exon v6 Are Crucial for the CD44v6 Coreceptor Function, and Small Peptides Can Interfere with This Function	38
3.5	The Ectodomain of CD44v6 Binds to HGF	42
3.6	Peptides Corresponding to Exon v6 of CD44 Inhibit Metastatic Spread of Tumor Cells	43
3.7	The Significance of the Collaboration between CD44v6 and c-Met <i>In Vivo</i>	45
3.8	The CD44v6 Peptides Interfere with Angiogenesis	46
3.9	Outlook	48
	References	49
4	Peptide Aptamers Targeting the Viral E6 Oncoprotein Induce Apoptosis in HPV-positive Cancer Cells	57
	<i>Felix Hoppe-Seyler, Susanne Dymalla, Markus A. Moosmeier, and Karin Hoppe-Seyler</i>	
4.1	Human Papillomaviruses and Oncogenesis	57
4.1.1	Cervical Cancer	58
4.1.2	The E6 and E7 Genes	59
4.2	Peptide Aptamers Targeting the HPV E6 Oncoprotein	61
4.3	E6-Targeting Peptide Aptamers: Therapeutic Perspectives	64
4.3.1	Therapeutic Target Protein Evaluation by Peptide Aptamers	64
4.3.2	The Intrinsic Therapeutic Potential of Peptide Aptamers	65
4.3.3	Identification of Functional Peptide Mimics by Displacement Screening	67
4.4	Perspectives	68
	References	69
5	The Prevention of HIV Infection with Viral Entry Inhibitors	73
	<i>Lisa Egerer, Anne Hubert, Dorothee von Laer, and Ursula Dietrich</i>	
5.1	Introduction: The Potential of Peptides as Drugs in the Treatment of HIV Infection	73
5.2	The HIV Entry Process	75
5.3	Peptides that Inhibit Receptor or Coreceptor Binding	77
5.3.1	Physiological Antimicrobial Peptides	77
5.3.1.1	Defensins	77
5.3.2	Chemokines	78
5.3.3	Synthetic Peptides and Peptidomimetics	79

5.4	Inhibitors of the Viral and Cellular Membrane Fusion Process	81
5.5	Entry Inhibitory Peptides Selected by the Phage Display Technology	83
5.6	Limitations of Peptides in the Treatment of HIV Infection	84
5.7	Strategies to Prolong the <i>In Vivo</i> Half-Life of Antiviral Peptides	85
5.8	Antiviral Peptides in Gene Therapy of HIV Infection	88
	References	93
6	Intracellular Expression of Peptides	103
	<i>Christian Wichmann, Yvonne Becker, and Manuel Grez</i>	
6.1	Introduction	103
6.2	Peptide Design and Expression Cassettes	103
6.3	Stable Delivery and Expression of Peptides: Gamma-Retro- and Lentiviral Vectors	106
6.4	Gamma-Retroviral Vectors	109
6.5	Lentiviral Peptide Delivery	111
6.6	Vectors for Transient Expression of Peptides: Adenoviruses and Adeno-Associated Viruses	114
6.7	Perspective	119
	Acknowledgments	120
	References	120
7	The Internalization Mechanisms and Bioactivity of the Cell-Penetrating Peptides	125
	<i>Mats Hansen, Elo Eriste, and Ülo Langel</i>	
7.1	Introduction	125
7.2	Discovery and Classification of CPPs	125
7.3	Internalization Mechanisms of Cell-Penetrating Peptides	126
7.4	Models of CPP Uptake	128
7.5	The Current View of CPP Uptake	129
7.6	CPPs as Cargo Delivery Vehicles	130
7.7	Delivery of Proteins	131
7.8	CPPs in Gene Delivery	131
7.9	Delivery of Oligonucleotides	131
7.10	Cytotoxicity of Cell-Penetrating Peptides	133
7.11	<i>In Vivo</i> Drug Delivery with CPPs	134
7.12	CPPs for Targeted Delivery	136
7.13	Conclusions	136
	Acknowledgments	137
	References	137
	Abbreviations	137

8	Production and Purification of Monomeric Recombinant Peptide Aptamers: Requirements for Efficient Intracellular Uptake and Target Inhibition	145
	<i>Corina Borghouts and Astrid Weiss</i>	
8.1	Introduction	145
8.2	Protein Production	146
8.2.1	Bacterial Systems	148
8.2.2	Yeast Systems	150
8.2.3	Baculovirus Systems	152
8.2.4	Chemical Synthesis	153
8.3	Protein Purification	154
8.3.1	Ammonium Sulfate Fractionation	154
8.3.2	Affinity Chromatography	155
8.3.3	Buffer Exchange and Desalting	156
8.3.4	Ion-Exchange Chromatography	156
8.3.5	Hydrophobic Interaction Chromatography	156
8.3.6	Size-Exclusion Chromatography	157
8.4	Isolation of Monomeric, Natively Folded Proteins	157
8.4.1	Correct Refolding versus Aggregation	157
8.4.2	Techniques for Protein Folding	158
8.4.3	Factors Influencing Refolding	159
8.5	Increasing Peptide Production, Purification and Efficacy by Using Scaffolds	161
8.5.1	Properties and Requirements of Scaffolds	161
8.6	The Use of Cell-Penetrating Peptides for Cellular Uptake of Purified Proteins	162
8.6.1	Uptake of Proteins by Lipid Raft-Dependent Macropinocytosis	164
8.6.2	Points of Consideration for the Use of CPPs	165
8.7	Classification of Therapeutic Peptides	167
8.7.1	Bioactive Peptides	167
8.7.2	Peptide Aptamers	168
8.7.3	Designed Peptides	171
8.7.4	Antibodies	172
8.8	Production and Administration of Therapeutic Peptides <i>In Vivo</i>	172
8.8.1	Extracellular Protein Therapeutics and Peptides with Extracellular Targets	172
8.8.2	Peptides Targeting Intracellular Targets <i>In Vivo</i>	173
8.9	Concluding Remarks	175
	References	176
9	Peptide Arrays on Solid Supports: A Tool for the Identification of Peptide Ligands	187
	<i>Mike Schutkowski, Alexandra Thiele, and Joachim Koch</i>	
9.1	Introduction	187
9.2	Synthesis of Peptide Arrays	188

9.2.1	Fmoc-Based Synthesis of Peptides on Cellulose Membranes	188
9.2.2	Fabrication of CelluSpots	190
9.2.3	Generation of Peptide Arrays with a Laser Printer	191
9.2.4	Generation of Peptide Arrays on a Compact Disc Device	191
9.2.5	Generation of Peptide Arrays by Chemoselective Immobilization	191
9.3	Applications of Peptide Arrays	193
9.3.1	Generation of Small Amounts of Soluble Peptide Libraries	193
9.3.2	Epitope Mapping of Monoclonal Antibodies	194
9.3.3	Investigation of Antibody Epitopes in Polyclonal Sera	195
9.3.4	Investigation of Protein–Protein Interactions	196
9.3.4.1	General Considerations	196
9.3.4.2	Identification of Enzyme Substrates	197
9.3.5	Mapping of Protein–Nucleic Acid Interactions	202
9.3.6	Screening for Antimicrobial Peptides	202
9.3.7	Identification, Characterization, and Optimization of Peptidic Ligands	204
9.3.8	Identification of Metal Ion-Selective Peptides	204
9.4	Challenges in High-Throughput Screening (HTS)	205
9.5	Future Perspectives	206
	Acknowledgments	207
	Abbreviations	207
	References	207

Index	219
--------------	-----

1

Peptides as Drugs: Discovery and Development*Bernd Groner*

“The necessity to exploit new drug targets and the suitability of peptides as drugs.”

1.1

Discovery of New Potential Drug Targets and the Limitations of Druggability

Complex networks of interacting proteins constitute the signaling pathways which mediate the intracellular propagation of biological information. Signals can originate from the cell surface and be relayed to sites in the cell where a biological response is triggered. The recognition of receptors by specific ligands is usually the initiating event which regulates cellular homeostasis, but also causes cellular responses such as proliferation, migration, angiogenesis, immune responses and cell death. The transient assembly of higher-order protein complexes, mediated by specific protein interaction domains and often regulated by secondary protein modifications, underlies the signaling mechanisms. In many instances platform proteins, for example, bring together enzymes and substrates and, in turn, recruit negative regulators which assure the transient nature of the signaling processes. The high complexity of these interactions makes them susceptible to disturbances arising from mutations in participating components, and the deregulation of specific protein–protein interactions has been recognized as the cause of diverse diseases. Conversely, the aberrant interaction of proteins is often a hallmark of diseased cells, and the inhibition of interactions required either to initiate or to maintain a particular disease state provides challenging opportunities for targeted therapies.

The importance of specific protein interactions has not only been recognized for diseases which originate from mutations in endogenous genes, but also extends to exogenous causes of disease and pathogenic microorganisms. Today, many disease-causing organisms and diseases are starting to be understood in molecular detail [1], with almost 600 microbial genomes having already been sequenced and 1800 others currently under investigation. This has led to the

identification of virulence genes, metabolic pathways and cell-surface proteins as new targets for antimicrobial drug development and candidate vaccines. New directions are primarily set by technologies aimed at the elucidation of global gene expression patterns, and these high-throughput molecular profiling techniques have accelerated the discovery of drug targets. Genomics, transcriptomics and proteomics not only play a decisive role in the investigation of infectious diseases, but also are becoming increasingly important in the understanding of multigenic human diseases such as diabetes, heart diseases and cancer [2]. However, the task to integrate such global and descriptive analyses into manageable models has only just begun, and the large and unwieldy datasets available not only still preclude the rational prediction of gene functions in an organismal context, but also hamper predictions about the benefits and side effects of targeted drugs.

The present limitations concerning the evaluation and interpretation of datasets collected from global gene expression patterns are not deterring progress, however. Today, large-scale efforts are under way to gain insights into whole genome alterations that distinguish cancer cells from their normal counterparts [3, 4]. Cancer cells exhibit multiple genetic alterations in their DNA sequences, in the number of individual genes, and in their epigenetic DNA and histone modifications. These alterations cause both the activation and inhibition of biological events, interpretable in the context of the pathophysiology of cancer cells [5]. The comparison of the human genome which is present in normal, healthy cells with that present in breast, colon, pancreatic cancer cells and glioblastomas, has shown that hundreds of genes can be present in mutated forms. Although about 60 genes have been found to be altered in individual tumors, the mutations varied when individual tumors were compared. Initially, it seems difficult to distinguish molecular alterations which are causal and drive tumor-related phenotypes, such as cell proliferation, cell death, metabolism, metastasis, angiogenesis or immune evasion, and those which are correlative and do not contribute to tumor formation. Nevertheless, consistent patterns could be identified. The most important mutations affect a limited number of cellular signaling pathways. The suggestion is that, interference with these pathways—but not necessarily the targeting of mutated gene products—might represent the most promising approach to therapy [3].

Elucidation of the functions of many of mutated gene products supports the overriding importance of deregulated pathways. Both, oncogenes and tumor suppressor genes control crucial points in the cell cycle, transitions from a resting stage (G_0 or G_1) to a replicating phase (S), inhibit cell growth, and stimulate cell death when induced by cellular stress [6]. The cells continuously respond to 'prods' emanating from external and internal signals. The oncogene and tumor suppressor gene products are usually components of signaling cascades and are integrated in networks of protein interactions. These protein interactions are most frequently regulated through post-translational modifications [7]. Proteins such as histones, p53, RNA polymerase II, tubulin, Cdc25C and tyrosine kinases can be modified at multiple sites through phosphorylation, acetylation, methylation, ubiquitination, sumoylation, and citrullination. These modifications can act in a com-